To compare and evaluate drug notations in outpatient medical records and in pharmacy records in a cohort of HIV-1-infected patients treated with antiretroviral drugs.
www.theannals.com I ndividuals infected with HIV-1 are frequently confronted with opportunistic infections and malignancies. Due to this comorbidity, these patients generally receive numerous drugs, prescribed by both general practitioners and the infectious disease specialists. A regimen consisting of 2 nucleoside analog reverse transcriptase inhibitors (NRTIs) as a backbone in combination with a nonnucleoside reverse transcriptase inhibitor (NNRTI) or 1 or 2 protease inhibitor(s) (PI) is the current standard of treatment of HIV-1-infection. 1 NNRTIs and PIs are extensively metabolized by the cytochrome P450 system, and are therefore subject to pharmacokinetic interactions when used in combination with drugs metabolized via the same pathways. 2, 3 In the Netherlands, the antiretroviral regimen of each HIV-1-infected individual is initiated and adjusted by the infectious disease specialist. The general practitioner only repeats the prescription of antiretroviral drugs and is mainly involved in the prescription of comedication.
HIV-1-infected patients obtain all of their prescribed drugs at their community pharmacy (except for drugs available through compassionate-use programs and research studies in the hospital), where a computer-based system documents each drug dispensation per patient. The involvement of different physicians, unaware of the drugs prescribed by colleagues, may lead to unwanted drug-drug interactions, potentially resulting in either increased frequency of adverse effects or failure of therapy due to reduced exposure to antiretroviral drugs.
It is important that each physician who is involved in the treatment of these patients is aware of the extent of drug use when assessing the patient's response to therapy in order to make appropriate therapeutic decisions (dosage adjustment, medication initiation, or discontinuation). In the hospital, this information is obtained from the outpatient medical record and from the patient by interview during routine visits at the outpatient clinic.
Corelli et al. 4 performed a study investigating the discrepancy between patient-reported medication use and that documented in the medical record by healthcare providers in an HIV-infected population. The results showed differences for the as-needed class of drugs (56-92%) as well as for drugs used chronically (9-54%). Another trial 5 compared computer-based prescription records with medical record drug entries for antihypertensive drugs. The information in the medical record and the prescription file from the outpatient pharmacy did not match in 5-14% of the drug entries when only the drug name was taken into account. Nonmatching dose information ranged from 14% to 21%. To our knowledge, no studies have been reported in which outpatient medical records from HIV-1-infected individuals were compared with pharmacy records.
The objective of this study was to compare drug notations in outpatient medical records and in pharmacy records in a cohort of HIV-1-infected patients treated with antiretroviral drugs. The outcome of this study may aid in further optimization of the complex pharmacotherapy of HIV-1-infected individuals with drug prescriptions from different sources.
Methods

PATIENTS AND DATA COLLECTION
HIV-1-infected patients, treated at the outpatient clinic of the Department of Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, were asked to give their written approval for use of their pharmacy records. The institutional review board of the Slotervaart Hospital approved the study protocol.
A retrospective chart review was performed; drug notations appearing in the pharmacy record were compared with the medical record in the hospital from January 1, 1998, through December 31, 1999. In the Netherlands, computer-based systems document each drug dispensation per patient and are known to be complete when it concerns recording of drug deliveries. 6 Pharmacy records are thus regarded the "gold standard" in this study. The community pharmacies were contacted and asked for their cooperation by providing the pharmacy records of these patients. Community pharmacies in the Netherlands are using different computerbased systems for recording drug dispensation. These different systems, and the fact that not every patient has been registered with the current community pharmacy for the same period, results in different follow-up of pharmacy records. If pharmacy records had overlap with 1997 or 2000, selections were made; only drugs that were stopped after January 1, 1998, or were initiated before January 1, 2000, were included in the analysis.
Data were collected from the medical records during the complete study period, but the analysis was only done for the period covered by each patient's pharmacy record. Each drug notation in the medical record made at a routine visit of the patient at the outpatient clinic, and information about drug use mentioned in correspondence between the infectious disease specialist, other specialists in the hospital, and the patient's general practitioner were documented. Drug name, drug formulation, strength, frequency of dosing, and the dates of initiation and termination of the drug were obtained.
Data from the pharmacy records and the medical records were incorporated in a database in Visual FoxPro 6.0 (Microsoft Corporation, Redmond, WA). Since the medical records often did not contain all information needed for the collection of data (mainly the exact date of initiation and termination of comedication were lacking), assumptions had to be made to perform the analysis ( Table 1) .
ANALYSIS
Generic Name Only
Generic names of antiretroviral drugs and comedication in the outpatient medical records were documented and compared with their appearance in the pharmacy records. Using the documented drugs in the pharmacy record as a criterion, a drug was recorded as a match when the same drug appeared in the outpatient medical record. The concordance was determined by calculating the ratio of matching drugs and total number of dispensed drugs; discrepancy is then the percentage that is nonconcordant. Drugs were classified according to the Anatomical Therapeutical Chemical (ATC) classification index. 7 The first level (anatomic main group, i.e., the site at which treatment is directed) of the ATC code was used to determine the discrepancy in the different groups of comedication. Plasters, topical pharmacy-made products, and similar formulations that are not classified in an ATC-code group were classified as "miscellaneous" in group Z. For the antiretroviral drugs, the discrepancy was subdivided into each drug separately.
Generic Name, Formulation, Strength, Dosing Frequency
A detailed comparison was performed at 5 time points during the study period for the antiretroviral drugs only. The time points that were chosen for the analysis were: May 1, 1998; October 1, 1998; March 1, 1999; August 1, 1999; and December 1, 1999. Each of these time points resulted in a different cohort of patients, since not every patient had a pharmacy record that started January 1, 1998, and continued until December 31, 1999. In the first part of this analysis, drug notations appearing in the pharmacy record at the specific time points were compared with those in the outpatient medical record and, if identical, were regarded as a match. This comparison was done on generic name, regardless of the brand name that was prescribed or dispensed. As with the first analysis, concordance was determined by calculating the ratio of matching drugs and number of total dispensed drugs in that cohort at that time point; discrepancy is then the percentage that is nonconcordant.
The second part of this analysis focused on the formulation, strength, and dosing frequency per day of the antiretroviral drugs. These components of drug use in the outpatient medical records were compared with those in the pharmacy records, and concordance was again calculated by determining the ratio of matching drugs and total dispensed drugs in that cohort. For both analyses, the assumption was made that Combivir (a coformulation of zidovudine and lamivudine) was not equal to the constituent drugs separately. This assumption was made for practical rea- sons, because 1 record for Combivir in the pharmacy record (1 dispensed) would otherwise be associated with 2 records in the medical notes.
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Results
The data from pharmacy records and outpatient medical records of 103 HIV-1-infected patients (95 men) were included in this study. The median age of these patients at baseline was 43 years (interquartile range 38-50). Duration of follow-up ranged from 2 months through 2 years (mean 1.4 y), with a total drug history of 148.3 years.
ANALYSIS
Generic Name Only
In this cohort of 103 patients, the total number of drugs dispensed was 1607, with antiretroviral drugs accounting for 22.8% (n = 366) and comedication accounting for 77.2% (n = 1241). The total discrepancy during the period from January 1, 1998, through December 31, 1999, was 55.1% (n = 885). Within each group, the discrepancy for the antiretroviral drugs and the comedication was 7.1% (n = 26) and 69.2% (n = 859), respectively.
The percentage of discrepancy of the different ATCcode groups of comedication is presented in Table 2 . High discrepancy was mainly observed in the miscellaneous group (Z, 96.7%), the group of the sensory organ agents (S, 94.4%), drugs used for the urogenital tract and sex hor-mones (G, 87.5%), and dermatologic agents (D, 87%), whereas a relatively low discrepancy was observed for the systemic hormonal preparations (H, 44.4%), drugs for the blood and blood-forming organs (B, 41.7%), and oncolytics and immune modulators (L, 33.3%).
In this population, the 10 most frequently coadministered drugs were trimethoprim/sulfamethoxazole (TMP/ SMX), loperamide, temazepam, cetirizine, miconazole, diclofenac, fluconazole, acyclovir, azithromycin, and doxycycline ( Table 3 ). The discrepancy for each drug varied between 23% and 88%, and was relatively high for miconazole (88%), temazepam (73.3%), diclofenac (72.7%), and acyclovir (71.4%). Relatively low discrepancy was observed for TMP/SMX (23%), doxycycline (31.6%), fluconazole (38.1%), and cetirizine (40.7%).
The antiretroviral drugs presented a discrepancy of 7.1%. Drugs that had a large contribution to this discrepancy were zidovudine (16.7%), ritonavir (10.8%), nevirapine (10.4%), and Combivir (10%) ( up period. Abacavir, efavirenz, delavirdine, and amprenavir were not marketed at the time of analysis, but were available through so-called compassionate-use programs. Patients who were receiving these antiretroviral drugs as part of their therapy obtained them through the outpatient clinic and hospital pharmacy of the Slotervaart Hospital and not via their community pharmacy, thus discrepancy for these drugs could not be determined.
Generic Name, Formulation, Strength, Dosing Frequency
The results of the second analysis, in which 5 cohorts at different time points during the study period were formed, are presented in Table 5 . The number of patients in these cohorts increased with time, because more pharmacy records were taken into account in the most recent cohorts. Fewer than 3 drugs per person were used, in spite of the conventionally used triple therapy. This is explained by the use of Combivir. Another explanation, of minor concern, is the compassionate-use programs in the hospital.
Using the generic name only, the discrepancy in the 5 different cohorts fluctuated from 5.1% to 12.6%, whereas the discrepancy for the analysis when formulation, strength, and dosing frequency were taken into account fluctuated from 7.1% to 17%. This more detailed comparison focusing on the 5 time points showed discrepancies that were overall somewhat higher than those in the first analysis.
Discussion
With the comparison of drug notations over a defined period of time, we found discrepancy between the 2 systems evaluated. This showed that 1 of the physicians involved was not aware of all of the medications being used, possibly resulting in problems such as drug-drug interactions.
The observed total discrepancy between outpatient medical records and pharmacy records mainly concerned the comedication. The high discrepancy in ATC-code group Z and the group of drugs used dermatologically may not be clinically relevant in most cases, but discrepancy in groups of the musculoskeletal agents, the central nervous system, the respiratory tract, and cardiovascular agents may be re-garded relevant. To interpret the relevance of high discrepancy, it is important to know the frequency of prescribing of certain drugs; those from groups with high discrepancy could be drugs that are rarely prescribed. Miconazole, temazepam, diclofenac, and acyclovir are among the 10 most frequently coadministered drugs. Miconazole is primarily used dermatologically. Temazepam, diclofenac, and acyclovir are used systemically (acyclovir is also used dermatologically), but are not susceptible to major drug-drug interactions. Nevertheless, in addition to the potential of drug interactions, it is also important to be aware of the drug use of each patient if adverse events occur. Without complete knowledge of the medication regimens, it is not possible to make a correct evaluation of the efficacy and/or toxicity of drugs, especially in this population in which multiple-drug regimens are very common.
The discrepancy in drug notations of the antiretroviral drugs was 7.1% in the first analysis. Discrepancy was observed for all antiretroviral drugs, with zidovudine showing the highest percentage. Because the discrepancy in antiretroviral drugs was not restricted to Combivir and lamivudine or zidovudine, the assumption to evaluate Combivir as a single drug could not have influenced the results. Antiretroviral drugs, like lamivudine and stavudine, with relatively low discrepancy, are the drugs most frequently used in this population; lamivudine and stavudine were part of the antiretroviral regimen of 67 and 62 patients, respectively, whereas 12 patients were prescribed zidovudine as part of the antiretroviral regimen. The drugs that are susceptible for drug-drug interactions, PIs and NNRTIs, showed relatively low, but substantial discrepancy.
The second analysis at the 5 time points using generic name only showed a discrepancy between 5.1% and 12.6%. As a consequence of a more detailed analysis, the discrepancy was slightly higher compared with that shown in the first analysis. While the community pharmacy uses the prescribed daily units and the total amount of units dispensed to calculate the duration of drug exposure of an antiretroviral drug, the infectious disease specialist knows exactly the duration of drug exposure as he/she is the one who initiates and stops the use of these drugs. The infectious disease specialist can, for instance, discontinue an an-
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The Annals of Pharmacotherapy ■ 2002 March, Volume 36 ■ 413 www.theannals.com Analysis of antiretrovirals when formulation, strength, and frequency of dosing per day were also taken into account. tiretroviral regimen because of virologic failure, while the community pharmacy believes that this regimen is still in use based on the patient's pharmacy records. This could explain the somewhat higher discrepancy in drug exposure at a specific time point. When strength, frequency of dosing, and formulation were taken into account, the discrepancy increased to values between 7.1% and 17%. This was primarily due to differences in or lack of documentation of the formulation and strength of the antiretroviral drug (ritonavir liquid and capsule, and stavudine 30 and 40 mg). West et al. 8 showed similar results in their study on the completeness of medical records for drug therapy relative to a database of dispensed pharmaceuticals. Of the 501 medical records reviewed, 11% of dispensed nonsteroidal antiinflammatory drugs (NSAIDs) were not entered into the medical record as having been prescribed to the patient. Comparable to our analysis in which discrepancy was obtained at specific time points, those investigators abstracted data from the medical record 1 month before the date the NSAID was dispensed.
In the Netherlands, the prescription of antiretroviral drugs is primarily assigned to the treating physician (infectious disease specialist) of the HIV-1-infected patient, whereas the general practitioner as well as other physicians at the outpatient clinic can be involved in the prescribing of comedication. The infectious disease specialist informs the general practitioner on a regular basis about changes in the course of the disease, antiretroviral regimen, and inititation or discontinuation of comedication. However, information about changes in the drug regimen performed by the general practitioner hardly ever reaches the specialist. In this case, the only source of information for the infectious disease specialist is the patient. Unfortunately, patients visit the outpatient clinic approximately every 3-4 months, and do not always remember the details about their prescribed drugs. Studies 9,10 show that a patient's recall of drug use increases when drugs are used chronically, and is better for drugs used recently than for drugs used earlier. The infectious disease specialist is usually notified of the prescription of drugs by other specialists at the outpatient department of the hospital by letters, which are kept in the medical records as additional information. The lack of exchange of all information by different parties involved, however, results in incomplete or absent drug notations in the medical records in the hospital.
That full exchange of information is pivotal became clear from an observation we made during this study. 11 We noticed from the pharmacy records that some patients were using both St. John's wort and nevirapine. Both agents were recorded in the pharmacy record, but the use of St. John's wort was not documented in the medical record. This alerted us to further investigate the exposure to nevirapine when St. John's wort was used concomitantly, because earlier published data 12 showed that lowered indinavir concentrations occur with concomitant use of St. John's wort. We showed that St. John's wort also decreased nevirapine concentrations by increasing its oral clearance, probably by induction of the cytochrome P450 enzyme system. Decreased nevirapine concentrations may eventually result in treatment failure by the development of nevirapine-resistant virus. In this case an herb, which is often not documented in the pharmacy records, showed that full awareness of all drug use is very important to optimize therapy.
Discrepancy between medical records and pharmacy records has not been investigated intensively thus far. Both Leister et al. 13 and Christensen et al. 5 determined the completeness of records for drugs ordered to and received by outpatients. They found discrepancies in drug names of 36% and 5-14% of the records, respectively, and in dosage information of 61% and 14-21%, respectively. Although both groups of researchers used on-site clinic pharmacies for the collection of data, discrepancies varied. Compared with these results, the discrepancy of comedication determined with use of generic name only in this study was relatively high, but may be the result of data from 2 separate institutions of recording of drug notations. This discrepancy of comedication will probably be even higher when records are examined at specific time points or within specific time windows. Discrepancy of antiretroviral drugs in both analyses was relatively low. This can probably be explained by the fact that only 1 prescriber (infectious disease specialist) was involved.
Summary
The observed discrepancy between drug notations in outpatient medical records compared with pharmacy records was mainly determined by comedication. Antiretroviral therapy has shown less but still substantial discrepancy (up to 17%). Discrepancy in drug notations of different sources may jeopardize effective therapy and lead to problems such as unwanted drug-drug interactions resulting in adverse effects. Our results indicate that full exchange of information concerning drug use in this population is lacking, but pivotal.
